Innate Pharma S.A. (0EVI.L)

3,0281 +0,0442 (+1,48%) Alla chiusura: 06:19PM BST

Innate Pharma S.A.

117, Avenue de Luminy
BP 30191
Marseille 13009
France
33 4 30 30 30 30
https://www.innate-pharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 179

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Herve Brailly Ph.D.	Co-Founder, Interim CEO & Chairman of Executive Board	N/D	N/D	1961
Mr. Yannis Morel Ph.D.	Executive VP, COO & Member of Executive Board	359,92k	N/D	1973
Dr. François Romagné Ph.D.	Founder	N/D	N/D	1964
Mr. Eric Vivier D.V.M., M.B.A., Ph.D.	Founder, Senior VP & Chief Scientific Officer	N/D	N/D	1964
Dr. Marc Bonneville Ph.D.	Founder	N/D	N/D	1960
Mr. Jean Jacques Fournié Ph.D.	Founder	N/D	N/D	N/D
Mr. Alessandro Moretta M.D., Ph.D.	Founder	N/D	N/D	N/D
Mr. Frederic Lombard M.B.A.	Senior VP & CFO	N/D	N/D	1975
Dr. Sonia Quaratino M.D., Ph.D.	Executive VP, Chief Medical Officer & Member of Executive Board	N/D	N/D	1967
Mr. Arvind Sood	Executive VP, President of US Operations & Member of Executive Board	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Governance aziendale

L'ISS Governance QualityScore di Innate Pharma S.A. al 29 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 1; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.